 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- | SCR430 / SupremeCure Pharma, RaND Biosciences
New P1/2 trial, Combination therapy, Metastases: A Phase 1/2 Study of SC-43 in Combination With Cisplatin (clinicaltrials.gov) - Feb 2, 2021
P1/2, N=100, Not yet recruiting, Sponsor: RaND Biosciences
- | SCR430 / SupremeCure Pharma, RaND Biosciences
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors (clinicaltrials.gov) - Oct 21, 2020
P1, N=0, Withdrawn, Sponsor: SupremeCure Pharma Inc.
N=45 --> 0 | Trial completion date: Nov 2021 --> Jun 2023 | Not yet recruiting --> Withdrawn | Trial primary completion date: May 2021 --> Dec 2022
- | SC-43 / SupremeCure
Journal: Radiometals for imaging and theranostics, current production and future perspectives. (Pubmed Central) - May 13, 2020
N=45 --> 0 | Trial completion date: Nov 2021 --> Jun 2023 | Not yet recruiting --> Withdrawn | Trial primary completion date: May 2021 --> Dec 2022 No abstract available
- || SCR430 / SupremeCure Pharma, RaND Biosciences
Trial completion date, Trial initiation date, Trial primary completion date: Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors (clinicaltrials.gov) - Apr 4, 2019
P1, N=45, Not yet recruiting, Sponsor: SupremeCure Pharma Inc.
No abstract available Trial completion date: Nov 2020 --> Nov 2021 | Initiation date: Nov 2018 --> Nov 2019 | Trial primary completion date: May 2020 --> May 2021
- | SCR430 / SupremeCure Pharma, RaND Biosciences
New P1 trial: Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors (clinicaltrials.gov) - Feb 23, 2018
P1, N=45, Not yet recruiting, Sponsor: SupremeCure Pharma Inc.